Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epoetin alfa vs placebo in anemic low- or intermediate-1-risk myelodysplastic syndrome
2010-022884-36Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2011
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in myelodysplastic syndrome (MDS) and anaemia comparing Epoetin alfa with Placebo (2 arms). Primary endpoint: Erythroid response at Week 24 (IWG 2006). Started Jun 2011; status: completed.
02
Drugs
epoetin alfa
03
Conditions
myelodysplastic syndrome (MDS)anaemia
Beyond the preview
Go deeper on 2010-022884-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022884-36.